GB2431581A - Ozonated oil formulations - Google Patents

Ozonated oil formulations Download PDF

Info

Publication number
GB2431581A
GB2431581A GB0621173A GB0621173A GB2431581A GB 2431581 A GB2431581 A GB 2431581A GB 0621173 A GB0621173 A GB 0621173A GB 0621173 A GB0621173 A GB 0621173A GB 2431581 A GB2431581 A GB 2431581A
Authority
GB
United Kingdom
Prior art keywords
oil
ozonated
compounds
skin
ozone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0621173A
Other versions
GB0621173D0 (en
GB2431581A8 (en
Inventor
Steven Karim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of GB0621173D0 publication Critical patent/GB0621173D0/en
Publication of GB2431581A publication Critical patent/GB2431581A/en
Priority to PCT/GB2007/050654 priority Critical patent/WO2008050157A2/en
Publication of GB2431581A8 publication Critical patent/GB2431581A8/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/40Peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/54Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22Peroxides; Oxygen; Ozone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/22Gas releasing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutically or cosmetically acceptable oil that has been ozonated with an amount of ozone less than the amount required to saturate the oil is disclosed.The oil may be used as a cosmetic formulation, such as a lip balm, moisturiser, facial cleanser, anti-aging product or massage oil. Alternatively the composition may be used in the treatment or prophylaxis of a dermatological condition, such as acne, psoriasis, eczema or skin cancer, or a dematological condition associated with Type diabetes. In a preferred embodiment, the oil is avocado oil.

Description

<p>Ozonated oil formulations</p>
<p>Description</p>
<p>The present invention relates to ozonated oils. In particular, it relates to oils ozonated to different levels, to pharmaceutically or cosmetically acceptable formulations comprising these oils for topical application to the skin, and to various pharmaceutical and cosmetic uses of these oils.</p>
<p>Research in the dermatological field is ever-expanding, not least because the skin is the largest organ of the body and plays a wide range of important roles. Common skin diseases or conditions include eczema, acne, psoriasis, skin cancer, viral warts and uticaria. Whereas some skin disorders are isolated, others arc symptoms of internal disease, such as rheumatic disease. Topically administered treatments are widespread, ranging from simple zinc-and titanium-based emollients to soothe and hydrate the skin, to creams containing active agents like antibiotics to treat infections and steroids to treat inflammatory conditions such as eczema and psoriasis. However, orally administered agents have also been used, such as the retinoid isotrenitoin for severe forms of acne, and ultraviolet light has been employed to treat diseases such as mycosis fungoides.</p>
<p>There are a number of problems with the known treatments for skin disorders. For instance, many antibiotic creams are too powerful for long-term use, and serious side effects have been associated with steroid therapy, including skin atrophy and steroid allergy. Alternatives to these creams have thus been keenly sought in the art.</p>
<p>There has been some investigation into ozonated pharmaceutical formulations, most commonly olive oil based formulations, as ozone is known to have useful properties such as microbicidal activity. For instance, FR 2,784,388 discloses the pharmaceutical and cosmetic use of oils such as olive oil that have been ozonated to saturation. US 4,451, 480 discloses ozonized oils such as olive oil, jojoba oil and sesame oil for topical application to the skin for the treatment of acne, which have an active oxygen content of about 0.1 to about 15 % by weight of the ozonide component.</p>
<p>There have been problems associated with ozonated olive oil formulations, however. WO 2006/021924 notes that ozonated olive oil is unstable due to its chlorophyll content and the relatively high concentration of short chain fatty acids relative to long chain fatty acids. It discloses ozonated avocado oil for therapeutic and cosmetic use and a method of producing such an oil. It notes that avocado oil has a higher concentration of long chain fatty acids relative to short chain fatty acids, and in the invention the chlorophyll naturally present is removed before ozonation. Nevertheless, this document does not consider suitable ozonation levels of the oil nor correlate these with particular pharmaceutical uses.</p>
<p>For a number of reasons, ozonated formulations have been slow to gain widespread acceptance for pharmaceutical use. If the majority of the known ozonated oils are applied to the skin on a regular basis, their high ozone concentration causes overstimulation of cells, producing undesired effects such as irritation, rashes and even rapid flaking of the skin. In some cases, the strong smell of ozone is unpleasant and causes the eyes to water. Furthermore, others of the known oils have non-specific physiological effects that are hard to control.</p>
<p>In seeking to overcome one or more of the above-mentioned problems, a range of ozonated oils have been developed that may be tailored to particular therapeutic uses, and that have also been found to have advantageous properties in the cosmetic</p>
<p>field.</p>
<p>Accordingly, in a first aspect of the invention there is provided a pharmaceutically or cosmetically acceptable oil that has been ozonated with an amount of ozone less than the amount required to saturate the oil.</p>
<p>In a second aspect of the invention there is provided avocado oil ozonated with 1.0 -6.0 g of ozone per 100 g of oil.</p>
<p>In a third aspect of the invention there is provided ozonated avocado oil containing 1.0-6.0 % ozonated compounds.</p>
<p>In a fourth aspect of the invention there is provided a pharmaceutically or cosmetically acceptable formulation comprising an oil according to the invention in any of its first to third aspects, for topical application to the skin.</p>
<p>In a fifth aspect of the invention there is provided a lip balm, moisturiser, facial, cleanser or anti-aging product, or massage oil comprising a formulation according to the invention in its fourth aspect.</p>
<p>In a sixth aspect of the invention there is provided the use of a formulation according to the invention in its fourth aspect as a lip balm, moisturiser, facial, cleanser or anti-aging product, or as a massage oil.</p>
<p>In a seventh aspect of the invention there is provided an oil according to the invention in any of its first to third aspects for use in therapy.</p>
<p>In an eighth aspect of the invention there is provided the use of an oil according to the invention in any of its first to third aspects for the manufacture of a medicament for USC in the treatment or prophylaxis of a dermatological condition, disease or disorder.</p>
<p>Preferred embodiments of the invention are as set out below or as defined in the sub-claims.</p>
<p>Figure 1 illustrates various regions of the skin and underlying adipose tissue, and penetration of ozone and/or ozonides through these regions.</p>
<p>The oils of the present invention have one or more beneficial properties and may be used as pharmaceuticals, cosmetics or so-called "cosmeceuticals". For instance, they may be antibacterial, antiviral and/or antifungicidal. They exert a rapid and efficient sterilizing effect, produce an improvement and acceleration of skin and tissue healing and are efficient immunoactivators.</p>
<p>They n-lay stimulate blood circulation, improving the rheological properties oi red blood cells, activating red blood cell metabolism, shifting the Hb02/Hb balance to the right and improving the release of oxygen. They may cause an increase in adenosine triphosphate (ATP), an increase in 2,3 diphosphoglycerate (2,3 DGP) and a drop in glutathione (GSH).</p>
<p>io In imrnunocompetent cells, the inventive oils may activate nuclear factor NFkB, and cause an induction and release of cytokines such as IL-I, IL-2, IFN-y, TNF-a and TGF-13.</p>
<p>The oils used have a maximum amount of ozone that can be incorporated, either by reaction or otherwise. The oils of the invention are ozonated with an amount of ozone less than this maximum amount required to "saturate" the oil. They have been found to have fewer side effects than the known saturated oils, whilst still maintaining therapeutic efficacy. In particular, skin is made up of several layers, including the epidermis, papillary dermis and reticular dermis, as shown in Figure 1, and the oils of the invention have various levels of action within the skin cells, blood cells, sebaceous glands, nerve tissue, muscle tissue and skin pores. By varying the concentration of ozone or ozonated species in the oil, the depth of penetration through the skin and the effects at a cellular level can be controlled and specifically tailored according to its desired use.</p>
<p>The well known cold corona discharge method may be used to produce so-called medical grade ozone (typically a 0.05 -5 % mixture of 03 and 02) from medical grade oxygen. The oil is placed into a pressurised vat and the medical grade ozone can then be bubbled through until the desired ozonation level has been reached.</p>
<p>The method disclosed in WO 2006/021924 may be used. Where the exact composition of the oil is batch dependent, one can take a known quantity of oil, measure the time required to ozonate to saturation and then calculate the time required to ozonate to the desired concentration.</p>
<p>In this manner, ozone is "stabilized" and the ozonated oil has a relatively long shelf life, e.,g. nvclve months if stored at low temperatures.</p>
<p>In a preferred embodiment of the invention, the oil contains unsaturated compounds, i.e. compounds bearing carbon-carbon double bonds. Preferably, these compounds are unsaturated fatty acids.</p>
<p>The exact composition and mechanism of action is not fully understood. However, it is believed that when ozone gas is introduced, at least part of it may react to form compounds such as ozonides, aldehydes or lipoperoxides. The Criegee mechanism may be involved in these reactions. When applied to the skin, the ozonation products may pass through to the intercellular space of red blood cells and immunocompetent cells to influence cellular metabolism.</p>
<p>At least a part of thc ozone introduced into the oil may remain in associated but unreacted form, for example in sequestered form or as a clathrate. Alternatively or in addition to the mechanisms outlined above, after application to the skin the ozone may be released and may break down to form oxygen free radicals, which are highly reactive and damage or destroy foreign organisms. Concurrently, it may stimulate the production of enzymes in the cell wall of the body's own cells such as glutathione peroxidase, catalase and superoxide dismutase, thus enhancing the cell wall resistance to attack by ozone.</p>
<p>The most preferred oil for use in the present invention is avocado oil. Analysis shows that the oil contains essential vitamins, minerals and fatty acids that are good for skin nutrition. In addition, it contains a rare DNA component that stimulates the skin to regenerate its own natural collagen (which provides skin elasticity).</p>
<p>Unlike other plant oils, it has a high natural concentration of antioxidants such as vitamin E, which are absorbed through the dermal layers and are known to combat aging of living cells. It is suspected that ozonation gives rise to a synergistic effect at a cellular level with the vitamin E naturally present, since vitamin E stabilizes the structure of the biomembrane by scavenging free radicals, protecting against the generation of damaging lipoperoxides in the biomembrane.</p>
<p>Where the oil to be ozonated contains chlorophyll, this can optionally be removed before ozonation.</p>
<p>The oil of the invention may be useful in the treatment or prevention of a variety of different dermatological conditions, diseases or disorders, including acne, actinic keratosis, angioma, aquagenic pruritus, athlete's foot, atopic dermatitis, baldness, basal cell carcinoma, bed sores, Behcet's disease, blepharitis, Bowen's disease, bullous pemphigoid, canker sores, carbuncles, cellulitis, chloracne, dyshidrosis, cold sores, creeping eruption, dermatitis, dermatitis herpetiformis, dermatofibroma, diaper rash, eczema, epidermolysis bullosa, erysipelas, erythroderma, genital warts, hidradenitis suppurativa, hives, hyperhidrosis, ichthyosis, impetigo, Kaposi's sarcoma, keloid, keratoacanthoma, keratosis pilaris, lichen planus, lichen simplex chronicus, lipoma, lymphadenitis, malignant melanoma, melasma, miliaria, molluscum contagiosum, nummular dermatitis, Paget's disease of the nipple, pediculosis, pemphigus, perioral dermatitis, photoallergy, pityriasis rosea, pityriasis rubra pilaris, psoriasis, Raynaud's disease, ring worm, rosacea, scabies, scieroderma, sebaceous cyst, seborrheic keratosis, seborrhoeic dermatitis, shingles, skin cancer, skin tags, spider veins, squamous cell carcinoma, stasis dermatitis, tick bites, tinea barbae, tinea capitis, tinea corporis, tinea cruris, tinea pedis, tinea unguium, tinea versicolor, tinea, tungiasis, vitiligo, or warts.</p>
<p>The formulation of the invention having an ozonation level of 1.0 -2.0 % is particularly suitable for use as a lip balm. It helps to prevent the lips from cracking and drying Out and is advantageously applied sparingly once to three times per day.</p>
<p>The low ozone concentration provides cellular granulation to the skin cells on the lips, allowing them to regenerate at an optimum rate thus accelerating healing time.</p>
<p>The formulation of the invention having an ozonation level of 2.0 -3.0 % is particularly suitable for use as a moisturiser. It is thought to primarily act on the epidermis, conditioning and brightening the complexion and regulating oil glands.</p>
<p>Angiogenesis promotes microcapillaries to increase blood circulation into the skin layers. The antioxidants such as vitamin E present in avocado oil also protect against environmental pollutants and free radicals generated by UV from the sun.</p>
<p>This formulation provides cellular granulation to the skin cells and neutralizes excess acids, balancing skin pH to a more alkaline level. It is preferably applied daily and to the face.</p>
<p>The formulation of the invention having an ozonation level of 3.0 -4.0 % is particularly suitable for use for facials, as a cleanser or as an anti-aging product. It is thought to primarily act on the epidermis and dermal layers, and provides an increased reaction process of repair and replication at a cellular level, cleaning the lymphatic channels around the face and providing antibacterial and viral protection against skin infection within the pores of the skin. This builds a much stronger layer of healthier skin cells, well before the cells mature, thereby lifting the tone and texture of the skin, providing soft smooth complexion with increased elasticity and delaying the aging process of the cells. Further, it cleanses sweat glands, neutralizes toxins and balances skin pH, reducing spots and pimples. It is preferably used once to three times per week, and stored in a dark and cool place out of direct sunlight.</p>
<p>The formulation of the invention having an ozonation level of 4.0 -5.0 % is particularly suitable for use as a massage oil, especially for sports massage. It is thought to act upon the epidermis, dermal layers, nerve and muscle tissue, conditioning the skin but also reducing aches and pains in muscles, reducing lactic acid build up and increasing ATP in the muscle cells. It aids healing of damaged muscles, ligaments and tendons, for instance in sports injuries, and can also be used to increase stamina in the muscles and reduce recovery periods after strenuous exercise or sports. It can be applied all over the body, or in specific areas such as to lymphatic zones to cleanse the lymphatic channels and lymph nodes and aid lymphatic circulation, and also to boost the immune system by increasing immunoproteins. It may be used every day, and is preferably stored in a cool dark place out of direct sunlight.</p>
<p>The formulation of the invention having an ozonation level of 5.0 -6.0 % is particularly suitable for use as a cosmeceutical or pharmaceutical. It penetrates deeply through the skin and can be used to treat a whole range of dermatological conditions including a wide spectrum of acne, cold sores and spots. It has a strongly sterilizing and cleansing effect, conditioning the skin to deal with most types of acne and spots. It can also be used to treat other skin ailments such as psoriasis, eczema, skin cancer and disorders associated with Type I diabetes. It may be used daily and left overnight, and may be applied sparingly over the affected area using an implement such as a cotton bud.</p>
<p>The oils of the invention range in colour and consistency depending on ozone concentration and temperature; they may take on a solid form with a creamy consistency or may be a viscous oil.</p>
<p>The oils may be used per Se, without any excipients. If desired, however, other cosmetically or pharmaceutically acceptable ingredients may be included in the formulations, such as aromatic essential oils to mask the odour of ozone.</p>
<p>Example I -Measurement of the effect of the ozonated oils of the invention on the oxygen supply in the skin Measurements of skin oxygen saturation (SO2) are carried out using a Whitland Research RM200 tissue SO2 monitor using two probes with different catchment depths: one which measures predominantly in the capillaries of the subpapilary plexus, the other which encompasses the venous plexus and some vessels of the deep dermal plexus.</p>
<p>Healthy human volunteers without a Latex allergy are accimatised at ambient 23 C for 15 minutes, and 3 sites of area approximately 1 cm2 are chosen on the right cheeks of the subjects and a fourth site on the left. The sites are chosen to avoid any visible veins, blemishes or pigmentations, and are marked discretely so that the same sites can be located for the subsequent measurements. Initial, baseline measurements with both probes are carried out at all four sites. On each occasion, approximately 10 measurements are made over the area of each site.</p>
<p>An ozonated oil of the invention is then applied by gentle massage to the first test site on the right cheek. The same oil, but not containing ozone, is similarly applied to the second site on the right cheek. The third site on the right cheek and the fourth site on the left cheek is similarly massaged, but without the application of any oil (both are considered as control sites, one on each sidc). Subsequent measurements are carried out at all 4 sites using the 2 probes at 30 minutes, 1 hour, 6 hours and 24 hours following application of the oils.</p>
<p>Results are analysed using the mean SO2 values measured at each site, treating the results from the 2 probes separately, and appropriate statistical techniques are applied.</p>
<p>Example 2 -Treatment of dyshidrotic eczema In the course of treating a female with dyshidrotic eczema, avocado oil ozonated to a concentration of 2.61 % was applied to her hands twice daily, in the morning and at night. After some initial inflammation on the right hand, both hands healed completely after a relatively short period of time. Use of this serum thus allowed the condition to be stabilized and healing occurred at a greater healing rate than with previously used products.</p>
<p>Example 3 -Treatment of acne Candida is an opportunistic yeast that normally resides harmlessly in the digestive system. In the abnormal state, however, Candida proliferates and converts into an invasive form to spread from the intestinal tract into the blood stream. This is known as a systemic Candida infection. One of the many symptoms from Candida is severe acne that ranges from white heads, papule, pustules and nodules.</p>
<p>A female who had been suffering with Candidasis for two years had all four symptoms of acne mentioned above. The healing rate of her skin was slow due to the life cycle of the nodules and papule, and her skin had very little time to recover due to new outbreaks that occurred regularly, especially when she menstruated.</p>
<p>She was given avocado oil ozonated to a concentration of 3.62 % to be massaged well into the affected areas for 10 minutes every night, and left to be absorbed overnight. In just under one month the outbreaks had begun to slow down, the redness had decreased by 70% and the purple colourisation had completely disappeared. The nodules had shrunk by 50%, the pain, itchiness and irritation had disappeared and only papule acne was coming out through the skin, decreased by 70%. With continued treatment the skin started to become soft and showed signs of smoothness. Subsequent new outbreaks, correlating with the timing of the patient's menstrual cycle, were less severe than previously experienced and began to heal at an accelerated rate, within a matter of days.</p>
<p>Example 4 -Treatment of acne A female presented a severe spread of acne (white heads and papules) around both shoulders and back. Previously used cleansing products and acne creams had had an effect but had not stopped the continuation of outbreaks of the spots. The papule spots cycle lasted a month before they disappeared.</p>
<p>Her treatment plan involved cleansing the affected areas with warm water and exfoliant, followed by application of sparing amounts of the serum directly onto the skin and massage with pressure for 20 -25 minutes until a warming heat was produced, twice per week.</p>
<p>Two days after the first treatment, the soreness and pain was no longer present.</p>
<p>Just before the third treatment the skin was soft and smooth in all the affected areas; all papules had been eliminated with no reoccurrence since the second treatment and all white heads have been eliminated apart from two fresh ones on the shoulders. After the third treatment, there was no reoccurrence of white heads or papules on the affected areas, and the skin remained bright, vibrant, smooth and soft. -11 -</p>
<p>The serum provided a superior healing rate and effective treatment for acne. It continued to work after each treatment due the ozonides that were stored at a cellular level to continue the healing process in between each of the treatment sessions.</p>

Claims (4)

  1. <p>Claims 1. A pharmaceutically or cosmetically acceptable oil that has
    been ozonated with an amount of ozone less than the amount required to saturate the oil.</p>
    <p>2. An oil according to claim 1, that has been ozonated with 10-70 % preferably 30 -50 %, of the amount of ozone required to saturate the oil.</p>
    <p>3. An oil according to claim 1 or 2, containing unsaturated compounds, preferably unsaturated fatty acids.</p>
    <p>4. An oil according to claim 3, containing a higher concentration of long chain fatty acids relative to short chain fatty acids.</p>
    <p>5. An oil according to any of the preceding claims, wherein at least part of the ozone reacts with the oil, preferably to form lipoperoxides, ozonides or aldehydes.</p>
    <p>6. An oil according to any of the preceding claims, comprising ozone in unreacted form, in sequestered form or as a clathrate.</p>
    <p>7. An oil according to any of the preceding claims, containing at least one antioxidant, preferably vitamin E. 8. An oil according to any of the preceding claims, comprising ozonated compounds capable of passage through to the intercellular space of red blood cells and immunocompetent cells upon application of said oil to the skin.</p>
    <p>9. An oil according to any of the preceding claims, which releases or causes the generation of active oxygen species, preferably free radicals or hydroxyl radicals, upon application to the skin.</p>
    <p>10. An oil according to any of the preceding claims, which traps free radicals or suppresses their generation in vivo.</p>
    <p>11. An ozonated avocado oil according to any of the preceding claims.</p>
    <p>12. Avocado oil ozonated with 1.0 -6.0 g of ozone per 100 g of oil.</p>
    <p>13. Ozonated avocado oil containing 1.0-6.0 % ozonated compounds.</p>
    <p>14. A pharmaceutically or cosmetically acceptable formulation comprising an oil according to any of the preceding claims, for topical application to the skin.</p>
    <p>15. A formulation according to claim 14, for delivery of ozonated compounds primarily to the epidermis.</p>
    <p>16. A formulation according to claim 14, for delivery of ozonated compounds primarily to the epidermis and papillary dermis.</p>
    <p>17. A formulation according to claim 14, for delivery of ozonated compounds to the epidermis, papillary dermis and reticular dermis, but not to adipose tissue.</p>
    <p>18. A cosmetic formulation according to any of claims 14 to 17.</p>
    <p>19. A lip balm, moisturiser, facial, cleanser or anti-aging product, or massage oil comprising a formulation according to claim 14.</p>
    <p>20. A lip balm according to claim 19, containing 1.0-2.0%, preferably 1.5-1.9 %, preferably 1.72 % ozonated compounds.</p>
    <p>21. A moisturiser according to claim 19, containing
  2. 2.0 -3.0 %, preferably 2.3 - 2.8 % preferably 2.59 % ozonated compounds.</p>
    <p>22. A facial, cleanser or anti-aging product according to claim 19, containing
  3. 3.0 -4.0 % preferably 3.4 -3.8 % preferably 3.61 % ozonated compounds.</p>
    <p>23. A massage oil according to claim 19, containing
  4. 4.0 -5.0 %, preferably 4.3 - 4.7 % preferably 4.50 % ozonated compounds.</p>
    <p>24. Use of a formulation according to claim 14 as a lip balm, moisturiser, facial, cleanser or anti-aging product, or as a massage oil.</p>
    <p>25. An oil according to any of claims I to 13 for use in therapy.</p>
    <p>26. Use of an oil according to any of claims 1 to 13 for the manufacture of a medicament for use in the treatment or prophylaxis of a dermatological condition, disease or disorder.</p>
    <p>27. Use according to claim 26 for the manufacture of a medicament for use in the treatment or prophylaxis of acne, psoriasis, eczema, skin cancer or a dermatological condition, disease or disorder associated with Type I diabetes.</p>
GB0621173A 2005-10-27 2006-10-24 Ozonated oil formulations Withdrawn GB2431581A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/GB2007/050654 WO2008050157A2 (en) 2006-10-24 2007-10-24 Ozonated oil formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0521873.0A GB0521873D0 (en) 2005-10-27 2005-10-27 Pure 03 serums

Publications (3)

Publication Number Publication Date
GB0621173D0 GB0621173D0 (en) 2006-12-06
GB2431581A true GB2431581A (en) 2007-05-02
GB2431581A8 GB2431581A8 (en) 2010-03-03

Family

ID=35515790

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0521873.0A Ceased GB0521873D0 (en) 2005-10-27 2005-10-27 Pure 03 serums
GB0621173A Withdrawn GB2431581A (en) 2005-10-27 2006-10-24 Ozonated oil formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB0521873.0A Ceased GB0521873D0 (en) 2005-10-27 2005-10-27 Pure 03 serums

Country Status (1)

Country Link
GB (2) GB0521873D0 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20110354A1 (en) * 2011-03-07 2012-09-08 Neovalis S R L COMPOSITION BASED ON OZONIZED OIL FOR TOPICAL USE
WO2013040721A1 (en) * 2011-08-10 2013-03-28 Hernandez Pavez Jose Octavio Method and system for producing ozonated natural oils and the application thereof in the treatment of humans, animals and vegetables, and in aquaculture
ITUB20155250A1 (en) * 2015-11-24 2017-05-24 Apuzzo Dario New nutraceutical composition, orally administered, useful for exercising a powerful stimulation of the metabolism, in particular of the muscular energy metabolism.
ITUB20156007A1 (en) * 2015-11-30 2017-05-30 S I P R E S S R L PROCEDURE FOR THE PRODUCTION OF OZONIZED NATURAL OILS AND OZONIZED NATURAL OIL MADE WITH THIS PROCEDURE
IT201600078872A1 (en) * 2016-07-27 2018-01-27 Fb Vision S R L OIL AND DEVICE FOR HYGIENE OF THE EYE AND PERIOCULAR AREA
IT201600111171A1 (en) * 2016-11-04 2018-05-04 Uras Cosmetics S R L S KIT FOR SKIN TREATMENT AND ITS USE
EP3506876B1 (en) * 2016-08-31 2021-03-03 Unigroup ApS Composition for nail fungus

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040108402A (en) * 2003-06-17 2004-12-24 주식회사 아이이아이 A Cosmetic including the oil of o·zone oxide
US20050113441A1 (en) * 1999-11-25 2005-05-26 Moraleda Manuel-Antonia G. Composition that comprises ozonised oils and/or other natural and/or synthetic ozonised products, and use thereof in pharmaceutical, cosmetic, dietary or food supplement products, in the human and veterinary fields
WO2006021924A1 (en) * 2004-08-26 2006-03-02 Pieter Josua Le Roux Therapeutic oil from plant origine
US20060074129A1 (en) * 2002-04-08 2006-04-06 Mirabal Jesus M Method for obtaining ozonized oils and vegetable fats and use of said products for pharmaceutical and cosmetic purposes
US20060153939A1 (en) * 2003-02-14 2006-07-13 Ordonez Jacome Neptali R C Method of obtaining and treating compounds from ozonized unsaturated vegetable oils for pharmaceutical compositions for medical and veterinary use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113441A1 (en) * 1999-11-25 2005-05-26 Moraleda Manuel-Antonia G. Composition that comprises ozonised oils and/or other natural and/or synthetic ozonised products, and use thereof in pharmaceutical, cosmetic, dietary or food supplement products, in the human and veterinary fields
US20060074129A1 (en) * 2002-04-08 2006-04-06 Mirabal Jesus M Method for obtaining ozonized oils and vegetable fats and use of said products for pharmaceutical and cosmetic purposes
US20060153939A1 (en) * 2003-02-14 2006-07-13 Ordonez Jacome Neptali R C Method of obtaining and treating compounds from ozonized unsaturated vegetable oils for pharmaceutical compositions for medical and veterinary use
KR20040108402A (en) * 2003-06-17 2004-12-24 주식회사 아이이아이 A Cosmetic including the oil of o·zone oxide
WO2006021924A1 (en) * 2004-08-26 2006-03-02 Pieter Josua Le Roux Therapeutic oil from plant origine

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20110354A1 (en) * 2011-03-07 2012-09-08 Neovalis S R L COMPOSITION BASED ON OZONIZED OIL FOR TOPICAL USE
WO2012120454A1 (en) * 2011-03-07 2012-09-13 Neovalis S.R.L. Composition for topical use based on ozonized oil
WO2013040721A1 (en) * 2011-08-10 2013-03-28 Hernandez Pavez Jose Octavio Method and system for producing ozonated natural oils and the application thereof in the treatment of humans, animals and vegetables, and in aquaculture
ITUB20155250A1 (en) * 2015-11-24 2017-05-24 Apuzzo Dario New nutraceutical composition, orally administered, useful for exercising a powerful stimulation of the metabolism, in particular of the muscular energy metabolism.
ITUB20156007A1 (en) * 2015-11-30 2017-05-30 S I P R E S S R L PROCEDURE FOR THE PRODUCTION OF OZONIZED NATURAL OILS AND OZONIZED NATURAL OIL MADE WITH THIS PROCEDURE
IT201600078872A1 (en) * 2016-07-27 2018-01-27 Fb Vision S R L OIL AND DEVICE FOR HYGIENE OF THE EYE AND PERIOCULAR AREA
WO2018020456A1 (en) * 2016-07-27 2018-02-01 Fb Vision S.R.L. Oil and device for cleaning the ocular and periocular area
EP3506876B1 (en) * 2016-08-31 2021-03-03 Unigroup ApS Composition for nail fungus
IT201600111171A1 (en) * 2016-11-04 2018-05-04 Uras Cosmetics S R L S KIT FOR SKIN TREATMENT AND ITS USE

Also Published As

Publication number Publication date
GB0621173D0 (en) 2006-12-06
GB2431581A8 (en) 2010-03-03
GB0521873D0 (en) 2005-12-07

Similar Documents

Publication Publication Date Title
KR100928211B1 (en) Compositions for the treatment of sun damage and compositions for reducing acne lesions
US8008345B2 (en) Dermal therapy using phosphate derivatives of electron transfer agents
GB2431581A (en) Ozonated oil formulations
KR100673044B1 (en) The composition for external use by percutaneous administration
US9579274B2 (en) Vitamin C composition for use in the prevention and treatment of stretch marks, radiation dermatitis, and other skin conditions and methods of using the same
WO2008050157A2 (en) Ozonated oil formulations
CN115429738B (en) Acne-removing, repairing and reviving essence and preparation method thereof
WO2002058640A1 (en) Topical therapeutic skin care system
Draelos et al. The effect of vehicle formulation on acne medication tolerability
US20180325973A1 (en) Skin care composition
EP3378474B1 (en) Composition for the use in the treatment of plantar hyperhidrosis predisposing to cutaneous fungal infection of the foot
CN112791093A (en) Transdermal drug delivery composition for treating acne and preparation method thereof
CN112402309A (en) Multi-vitamin mineral essence cream and preparation method thereof
US20210052524A1 (en) N-acetylcysteine and urea-based formulation for the treatment of dermatological disorders
RU2283642C1 (en) Anti-cellulitis cream
WO2007133641A1 (en) Enhanced protection against skin injury in humans
Chernoff A novel combination therapy in aesthetic and reconstructive surgery: sea salt, exfoliation, cavitating ultrasound, and high intensity multiwavelength LED treatment:(SaltFacial)
EP4085913A1 (en) Formulation comprising nicotinamide, zinc, copper and glutathione for treating acne rosacea
US8969411B2 (en) Vitamin C composition for use in the prevention and treatment of stretch other skin conditions and methods of using the same
RU2780260C1 (en) Cosmetic for skin
WO2018041319A1 (en) Composition for nail fungus
WO2009020398A2 (en) Skin care product
Mirodilova et al. OPTIMIZATION OF THE TREATMENT OF PATHOLOGICAL DRYNESS OF THE SKIN
AU2023203452B1 (en) Topical formulations
RU2577297C1 (en) Method for outpatient treatment of facial skin of patients with rosacea

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)